Welcome to our dedicated page for Cencora SEC filings (Ticker: COR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cencora, Inc. (NYSE: COR) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a large pharmaceutical solutions and distribution organization, Cencora uses its SEC reports to present detailed information about its financial performance, capital structure, governance, and significant transactions.
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports to understand Cencora’s revenue composition, segment performance for U.S. Healthcare Solutions and International Healthcare Solutions, and the impact of acquisitions such as Retina Consultants of America. These filings also describe non-GAAP measures like adjusted operating income and adjusted diluted earnings per share, along with reconciliations to GAAP metrics.
Cencora’s Form 8-K current reports offer timely updates on material events, including amendments to credit facilities, changes to its receivables securitization program, issuance and listing of senior notes, revisions to its reporting structure, and agreements to acquire additional equity interests in OneOncology. Other 8-Ks disclose governance developments, such as board appointments and leadership changes, as well as information about legal settlements and derivative actions.
Through Stock Titan, users can also track registered debt securities like Cencora’s 2.875% Senior Notes due 2028 (COR28) and 3.625% Senior Notes due 2032 (COR32), which are listed alongside the common stock. Where available, insider transaction reports on Forms 3, 4, and 5 can help users monitor equity ownership changes by directors and officers.
AI-powered tools on the platform summarize lengthy Cencora filings, highlight key changes from prior periods, and surface important disclosures about liquidity, financing arrangements, segment realignments, and legal matters. This helps readers quickly interpret complex documents and focus on the sections most relevant to their analysis of COR.
Cencora (NYSE:COR) filed a Form 4 reporting insider transactions by Executive Chairman Steven H. Collis on 24 June 2025.
Collis exercised 12,579 stock options at an exercise price of $86.09 (code M) and sold 14,579 common shares at an average price of $292.62 (code S) under a pre-arranged Rule 10b5-1 trading plan adopted 25 Nov 2024. The sale is valued at roughly $4.3 million.
Following the transactions he directly owns 311,912.665 shares of common stock and retains 113,206 outstanding options. The disposition represents about 4.7 % of his prior direct holdings, yet he continues to hold a substantial equity stake.
Cencora, Inc. (Form 144) – A notice of proposed insider sale has been filed for 14,579 common shares with an estimated aggregate market value of $4,266,106.98. The sale is expected to be executed on 06/24/2025 through Fidelity Brokerage Services on the NYSE.
The filing discloses that Cencora has 193,823,487 shares outstanding; the planned transaction therefore represents roughly 0.0075 % of the company’s total shares, indicating an immaterial effect on share count but providing insight into insider behavior.
Acquisition background:
- 2,000 shares acquired via restricted-stock vesting on 09/30/2023 (compensation).
- 12,579 shares acquired via option exercise dated 06/24/2025 (cash payment).
Recent insider activity (past three months):
- 03/25/2025 – 14,578 shares sold for $3,928,916.78
- 04/22/2025 – 14,579 shares sold for $4,108,507.99
- 05/20/2025 – 14,578 shares sold for $4,283,599.52
No relationship to the issuer is specified in the excerpt, and no Rule 10b5-1 plan adoption date is provided. The filer certifies that no undisclosed material adverse information is known at the time of filing.
Cencora, Inc. (COR) – Form 4 insider transaction
Executive Vice President Silvana Battaglia reported the sale of 4,077 common shares on 18-Jun-2025 at an average price of $297.405 per share. Following the transaction, Battaglia’s direct holding stands at 11,296.889 shares. No derivative securities were involved, and no Rule 10b5-1 plan was indicated. The filing was signed on 20-Jun-2025.
Cencora, Inc. (COR) – Form 4 insider activity dated 18 June 2025
President & CEO Robert P. Mauch reported two simultaneous transactions: (1) the exercise of 3,225 non-qualified stock options at an exercise price of $86.09 (code M) and (2) the open-market sale of 4,969 common shares at an average price of $295.30 (code S) pursuant to a pre-arranged Rule 10b5-1 plan adopted on 15 Nov 2024.
After the transactions, Mauch’s direct ownership declined from 49,063 to 44,094 shares, a net reduction of 1,744 shares (≈ 3.6 % of his post-transaction stake and ≈ 10 % of the shares he previously held). He retains 29,027 vested options expiring 13 Nov 2026.
- The option exercise converted derivative holdings into common stock, locking in a spread of roughly $209.21 per share between the sale price and strike price.
- The sale represents a cash realization of ≈ $1.47 million before taxes and fees.
- The transaction was executed under a 10b5-1 plan, which generally reduces concerns about opportunistic timing.
No company operational metrics, earnings data, or strategic announcements are included in this filing; its relevance is limited to insider-ownership trends.
Cencora, Inc. (symbol: COR) has filed a Form 144 with the U.S. Securities and Exchange Commission, indicating a proposed insider sale of common stock under Rule 144.
The notice covers the potential disposition of 1,000 common shares through broker Goldman Sachs & Co. LLC. The sale is tentatively scheduled for 18 June 2025 on the NYSE. At a stated aggregate market value of $293,200, the implied reference price is roughly $293.20 per share.
The filing shows the shares were originally granted to the seller as restricted stock awards on two dates—20 Aug 2013 (500 shares) and 09 Aug 2016 (500 shares)—as part of compensation from Cencora. No prior sales have been reported in the past three months, and the person filing affirms no knowledge of undisclosed material adverse information about the company.
Relative to the total outstanding share count of 193,823,487, the proposed sale represents approximately 0.0005 % of shares outstanding, suggesting minimal dilution or market impact. The filing is routine in nature, providing transparency around a small insider transaction rather than signaling any broader strategic change.
FAQ
What is the current stock price of Cencora (COR)?
What is the market cap of Cencora (COR)?
